Pharmaceutical major Cadila Healthcare Ltd and its subsidiary Zydus Pharmaceuticals (USA) Inc., on Friday, announced that they have finalised an agreement with Upsher-Smith Laboratories, Inc. to settle all outstanding patent litigation related to Qudexy® XR (topiramate) extended-release capsules.
Zydus Pharmaceuticals (USA) Inc. is a leading generic pharmaceutical company in the United States,
Under the terms of the agreement, Upsher-Smith will grant Zydus licence to market the latter’s (Zydus’) generic version of Qudexy® XR beginning on March 19, 2020, or earlier, under certain circumstances, according to a company statement here.
Other terms of the settlement were not disclosed.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.